Status:
TERMINATED
An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
For many years scientists and cancer researchers have been trying to find out why some people benefit more from anti-cancer medications than other people who receive the same amount and same kind of m...
Detailed Description
Epirubicin is an anthracycline that is widely used in breast cancer, stomach and esophageal cancer. Despite epirubicin being the 4'-epi-isomer of doxorubicin, epirubicin undergoes substantially differ...
Eligibility Criteria
Inclusion
- Receiving adjuvant or neoadjuvant FEC100
Exclusion
- Elevated bilirubin
- Abnormal liver or kidney function
Key Trial Info
Start Date :
January 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00131612
Start Date
January 1 2002
End Date
January 1 2013
Last Update
February 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2